Stay Up to Date
Breaking News,
Updates, & More
Click Here to

TOP - August 2015, Vol 8, No 3

Rolapitant 180 mg significantly reduced symptoms of chemotherapy-induced nausea and vomiting in patients treated with multiple cycles of highly or moderately emetogenic chemotherapy when compared with placebo in 4 double-blind, active-controlled studies.
The National Com­prehensive Cancer Network (NCCN) now recommends nivolumab (Opdivo) as subsequent therapy for metastatic squamous non–small-cell lung cancer (NSCLC) after its recent FDA approval.
Although recent studies have shown the efficacy of using ster­eotactic body radiation therapy (SBRT) as a treatment modality for organ-confined prostate cancer, questions over urinary symptoms and sexual dysfunction have remained.
  • Abiraterone and Metabolic Syndrome
  • Obesity and Survival in Metastatic Renal-Cell Carcinoma
  • Radium-223 and Pain
  • New Biomarker for Survival
  • Quality of Life in Long-Term Survivors of Bladder Cancer
A successful pharmacist-­driven drug-monitoring protocol can be achieved in a medical practice when necessary elements are considered.
A new clinical guideline for smoking cessation in patients with cancer encourages the use of evidence-based pharmacotherapy, behavioral therapy, and close follow-up with retreatment.
The Academy of Oncology Nurse & Patient Navigators® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeons Commission on Cancer (CoC).
In his NCCN update of the CLL guideline, Dr Wierda noted that the Bruton’s tyrosine kinase (BTK) inhibitor­ ibrutinib (Imbruvica) could soon replace conventional chemotherapy.
In this month’s issue of The Oncology Pharmacist, we present coverage of the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. We highlight presentations on the effectiveness of rolapitant for chemotherapy-induced nausea and vomiting, as well as data on the association between osteonecrosis of the jaw and medication.
With the exception of skin cancer, prostate cancer is the most common cancer affecting men.
Page 1 of 2
Results 1 - 10 of 15